Sabbin Bayanai Akan Ciwon Kwakwalwa Na Yara

Kazia Therapeutics Limited ta sanar da sabbin bayanai na asali waɗanda ke nuna ayyukan paxalisib a cikin nau'i biyu na kansar ƙwaƙwalwa na ƙuruciya tare da buƙatun likita da ba a biya su ba.       

Wannan bayanan shine batun taƙaitaccen bayani guda uku da aka gabatar a Taron Shekara-shekara na Ƙungiyar Nazarin Ciwon daji ta Amurka (AACR), wanda aka gudanar a New Orleans, LA, daga Afrilu 8 - 13, 2022.

Rubuce-rubuce biyu na masana kimiyya da ke aiki a dakin gwaje-gwaje na Mataimakin Farfesa Jeffrey Rubens a Jami'ar Johns Hopkins a Baltimore, MD, sun bayyana amfani da paxalisib a matsayin maganin kashin baya a cikin ciwon daji na kwakwalwar yara wanda aka sani da ciwan teratoid / rhabdoid (AT/RT). Wannan shi ne karo na farko da aka gabatar da bayanan binciken paxalisib a cikin wannan nau'i na ciwon daji na kwakwalwa, kuma yana buɗe wata muhimmiyar sabuwar alama ga miyagun ƙwayoyi.

Ƙididdigar ta uku, daga ƙungiyar masana kimiyya daban-daban a Jami'ar Johns Hopkins, wanda Mataimakin Farfesa Eric Raabe da Dr Katherine Barnett suka jagoranta, sun nuna shaidar haɗin gwiwa mai karfi tsakanin paxalisib da wani nau'i na maganin ciwon daji a cikin samfurin yaduwa na intrinsic pontine glioma (DIPG) . Paxalisib a baya ya nuna shaidar aiki a cikin wannan cuta, duka a matsayin monotherapy kuma a hade tare da nau'o'in maganin ciwon daji da yawa, kuma sabon bayanan ya kara tabbatar da yiwuwarsa a cikin wannan cuta mai kalubale.

Makullin Maɓalli

• AT/RT cutar kansar kwakwalwa ce da ba kasafai ake samunta ba wadda ta fi shafar jarirai da kananan yara. Babu magungunan FDA da aka amince da su don AT/RT kuma zaɓuɓɓukan warkewa na yanzu suna da iyaka. Kasa da ɗaya cikin biyar marasa lafiya sun tsira fiye da shekaru biyu daga ganewar asali.

Bayanai daga dakin gwaje-gwaje na Farfesa Rubens sun nuna cewa hanyar PI3K yawanci ana kunna ta a cikin AT/RT, kuma jiyya tare da paxalisib kadai yana aiki a cikin daidaitattun nau'ikan cutar. Haka kuma, haɗe tare da ko dai RG2822, mai hana HDAC, ko TAK580, mai hana MAPK, ya bayyana yana haɓaka rayuwa sosai idan aka kwatanta da maganin monotherapy.

DIPG wani ciwon daji ne na kwakwalwa wanda ba kasafai ake gani a kananan yara da matasa ba. Babu magungunan FDA da aka amince da su, kuma matsakaicin tsawon rayuwa daga ganewar asali yawanci matsakaita kusan watanni goma.

• Bayanan da suka gabata daga ƙungiyoyin masu bincike da yawa, kuma musamman daga ƙungiyar Farfesa Matt Dun a Cibiyar Nazarin Kiwon Lafiya ta Hunter, sun nuna cewa paxalisib yana aiki sosai a cikin DIPG kuma yana haɗuwa tare da magungunan ciwon daji da yawa.

Bayanai daga Drs Raabe da Barnett da abokan aiki sun gano ƙarin haɗin jiyya na sabon labari, tare da mai hana HDAC RG2833, wanda ke nuna shaidar haɗin gwiwa mai ƙarfi a cikin daidaitaccen samfurin DIPG.

Shugaban Kazia, Dokta James Garner, ya kara da cewa, "Wannan bayanai ne masu ban sha'awa, kuma muna godiya ga tawagar a Johns Hopkins don wannan bincike mai mahimmanci da karfafa gwiwa. Paxalisib ya riga ya zama batun ci gaba na gwajin gwaji na asibiti na II a cikin DIPG da kuma watsar da gliomas na tsakiya (NCT05009992) kuma wannan sabon bayanan yana nuna yiwuwar aikace-aikacen da za a iya amfani da su don maganin a cikin cututtukan kwakwalwa na yara. Muna sa ran yin aiki tare da ƙungiyar Johns Hopkins, da sauran abokan hulɗa da masu ba da shawara, don ƙarin bincika waɗannan damar. "